References
- Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic(and more) treatments for cancer. Nat Rev Cancer 2006;6:38–51.
- de Ruijter AJM, an Gennip AH, Caron HN, Kemp S, van Kuilenburg ABP. Histone deacetylases(HDACs): characterization of the classical HDAC family. Biochem J 2003;370:737–49.
- Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000;92:1210–16.
- Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 2008;269:7–17.
- Kim DH, Kim M, Kwon HJ. Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents. J Biochem Mol Biol 2003;36:110–19.
- Pan L, Lu J, Huang B. HDAC inhibitors: a potential new category of anti-tumor agents. Cell Mol Immunol 2007;4:337–43.
- Acharya MR, Sparreboom A, Venitz J, Figg WD. Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol 2005;68(4):917–32.
- Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007;12:1247–52.
- Patent application US 2000/6541661.
- Paris M, Porcelloni M, Binaschi M, Fattori D. Histone deacetylase inhibitors: from bench to clinic. J Med Chem 2008;5:1505–29.
- Wen-Fang X, Jie J. Preparation of cinnamamide derivatives as histone deacetylase inhibitors for treatment of cancer. In: Faming Zhuanli Shenqing Gongkai Shuomingshu 2008:1–11.